The estimated Net Worth of Howard Levy is at least $733 Tausend dollars as of 9 August 2021. Howard Levy owns over 639 units of Catalyst Biosciences Inc stock worth over $326 and over the last 8 years he sold CBIO stock worth over $0. In addition, he makes $733,018 as Chief Medical Officer at Catalyst Biosciences Inc.
Howard has made over 9 trades of the Catalyst Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 639 units of CBIO stock worth $2,313 on 9 August 2021.
The largest trade he's ever made was exercising 7,560 units of Catalyst Biosciences Inc stock on 3 May 2018 worth over $35,003. On average, Howard trades about 1,131 units every 66 days since 2016. As of 9 August 2021 he still owns at least 639 units of Catalyst Biosciences Inc stock.
You can see the complete history of Howard Levy stock trades at the bottom of the page.
Dr. Howard Levy Ph.D. serves as Chief Medical Officer of the Company. Dr. Levy had served as either a Chief Medical Officer or a consultant with various public and private biotechnology companies on clinical and drug development strategy and execution. In addition, Dr. Levy was the Senior Global Medical Program Director at the global biotechnology company CSL Behring in 2013, and he was the Senior Vice President and Chief Medical Officer at Inspiration Biopharmaceuticals, a company solely focused on innovation in hemophilia, in 2012. From 2008 to 2011, he served as Chief Medical Officer at Sangart, Inc., which was developing pegylated hemoglobin as an oxygen therapeutic agent and a treatment for sickle cell crisis. Prior to Sangart, from 2006 to 2008, Dr. Levy was Associate Vice President, Clinical Research, Medical and Regulatory Affairs at Novo Nordisk, a global healthcare company, and was responsible for a number of clinical research programs, including recombinant Factor VIIa. Earlier in his career, Dr. Levy was Clinical Research Physician and Medical Director, Acute Care in the U.S. Medical Division of Eli Lilly and Company, a pharmaceutical company, supporting post-marketing clinical trials and medical affairs for recombinant Activated Protein C (Xigris) in severe sepsis and antiplatelet agents ReoPro and prasugrel. He was also Chief of Critical Care Medicine at the University of New Mexico in Albuquerque for 11 years. Dr. Levy received his M.B. B.Ch and Ph.D. degrees from the University of the Witwatersrand in Johannesburg, South Africa and his M.M.M. from Carnegie Mellon University’s H. John Heinz III College.
As the Chief Medical Officer of Catalyst Biosciences Inc, the total compensation of Howard Levy at Catalyst Biosciences Inc is $733,018. There are 2 executives at Catalyst Biosciences Inc getting paid more, with Nassim Usman having the highest compensation of $1,198,860.
Howard Levy is 66, he's been the Chief Medical Officer of Catalyst Biosciences Inc since 2016. There are 1 older and 8 younger executives at Catalyst Biosciences Inc. The oldest executive at Catalyst Biosciences Inc is Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D., 67, who is the Consultant.
Howard's mailing address filed with the SEC is 260 Littlefield Ave, South San Francisco, CA 94080, USA.
Over the last 9 years, insiders at Catalyst Biosciences Inc have traded over $2,614,728 worth of Catalyst Biosciences Inc stock and bought 81,771 units worth $199,380 . The most active insiders traders include Jeff Himawan, James E Deerfield Mgmt L.P.... und Augustine Lawlor. On average, Catalyst Biosciences Inc executives and independent directors trade stock every 62 days with the average trade being worth of $3,315. The most recent stock trade was executed by Nassim Usman on 9 August 2022, trading 3,250 units of CBIO stock currently worth $1,528.
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.
Catalyst Biosciences Inc executives and other stock owners filed with the SEC include: